Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024
Unicycive Therapeutics (Nasdaq: UNCY), a clinical-stage biotech company focused on kidney disease therapies, has announced its participation in the virtual Lytham Partners Fall 2024 Investor Conference. Dr. Shalabh Gupta, the company's CEO, will engage in a fireside chat on October 1, 2024, at 11:00 a.m. ET.
Investors and interested parties can access the live webcast and archived recording through the Unicycive website's Investor section under Events and Presentations. The archived webcast will remain available for three months following the event, providing an extended opportunity for those unable to attend the live session.
Unicycive Therapeutics (Nasdaq: UNCY), un'azienda biotecnologica in fase clinica focalizzata sulle terapie per le malattie renali, ha annunciato la sua partecipazione alla virtual Lytham Partners Fall 2024 Investor Conference. Il Dr. Shalabh Gupta, CEO dell'azienda, parteciperà a una chiacchierata informale il 1 ottobre 2024, alle 11:00 ora ET.
Gli investitori e le parti interessate possono accedere alla diretta e alla registrazione archiviata tramite la sezione Investor del sito web di Unicycive sotto Eventi e Presentazioni. La registrazione archiviata rimarrà disponibile per tre mesi dopo l'evento, offrendo un'opportunità estesa a chi non può partecipare alla sessione dal vivo.
Unicycive Therapeutics (Nasdaq: UNCY), una empresa biotecnológica en etapa clínica centrada en terapias para enfermedades renales, ha anunciado su participación en la conferencia de inversores virtual Lytham Partners Fall 2024. El Dr. Shalabh Gupta, CEO de la compañía, participará en una charla informal el 1 de octubre de 2024, a las 11:00 a.m. ET.
Los inversores y partes interesadas pueden acceder a la transmisión en vivo y a la grabación archivada a través de la sección de Inversores del sitio web de Unicycive en Eventos y Presentaciones. La grabación archivada estará disponible durante tres meses después del evento, proporcionando una oportunidad ampliada para aquellos que no puedan asistir a la sesión en vivo.
유니사이시브 테라퓨틱스 (Nasdaq: UNCY), 신장 질환 치료에 집중하는 임상 단계의 생명공학 회사가 가상 Lytham Partners Fall 2024 투자자 회의에 참여한다고 발표했습니다. 샬라브 굽타 박사가 회사의 CEO로서 2024년 10월 1일 오전 11시(ET)에 화상 대담에 참여할 예정입니다.
투자자 및 관심 있는 당사자는 유니사이시브 웹사이트 투자자 섹션의 이벤트 및 프레젠테이션 항목을 통해 실시간 웹캐스트 및 녹화된 내용을 볼 수 있습니다. 아카이브된 웹캐스트는 이벤트 후 3개월 동안 사용 가능하여 실시간 세션에 참석할 수 없는 분들에게 연장된 기회를 제공합니다.
Unicycive Therapeutics (Nasdaq: UNCY), une entreprise de biotechnologie en phase clinique spécialisée dans les thérapies pour les maladies rénales, a annoncé sa participation à la conférence virtuelle des investisseurs Lytham Partners Fall 2024. Dr. Shalabh Gupta, le PDG de l'entreprise, participera à une discussion informelle le 1er octobre 2024 à 11h00 ET.
Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct et à l'enregistrement archivé via la section Investisseurs du site Web d'Unicycive dans les Événements et Présentations. L'enregistrement archivé sera disponible pendant trois mois après l'événement, offrant ainsi une opportunité prolongée pour ceux qui ne peuvent pas assister à la séance en direct.
Unicycive Therapeutics (Nasdaq: UNCY), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Therapien für Nierenerkrankungen konzentriert, hat seine Teilnahme an der virtuellen Lytham Partners Fall 2024 Investor Conference bekannt gegeben. Dr. Shalabh Gupta, der CEO des Unternehmens, wird am 1. Oktober 2024 um 11:00 Uhr ET an einem informellen Gespräch teilnehmen.
Investoren und Interessierte können über den Investmentbereich der Unicycive-Website unter Veranstaltungen und Präsentationen auf den Live-Stream und die archivierte Aufzeichnung zugreifen. Die archivierte Webcast steht drei Monate nach der Veranstaltung zur Verfügung und bietet so eine erweiterte Gelegenheit für diejenigen, die nicht an der Live-Sitzung teilnehmen können.
- None.
- None.
LOS ALTOS, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a fireside chat at the virtual Lytham Partners Fall 2024 Investor Conference on Tuesday, October 1, 2024 at 11:00 a.m. ET.
A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. For more information, please visit Unicycive.com and follow us on LinkedIn, X, and YouTube.
Investor Contact:
ir@unicycive.com
(650) 543-5470
SOURCE: Unicycive Therapeutics, Inc.
FAQ
When is Unicycive Therapeutics (UNCY) participating in the Lytham Partners Fall 2024 Investor Conference?
Who will represent Unicycive Therapeutics (UNCY) at the Lytham Partners Fall 2024 Investor Conference?
How can investors access the Unicycive Therapeutics (UNCY) presentation at the Lytham Partners Fall 2024 Investor Conference?
How long will the archived webcast of Unicycive Therapeutics' (UNCY) presentation be available?
What is the main focus of Unicycive Therapeutics (UNCY) as a biotechnology company?
